The National Law Review

RESTEM to Present Company Overview in Biotech Showcase 2026

MIAMI, Dec. 22, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today ...
The National Law Review

RESTEM to Present at the 2025 BIO International Convention

To register for the conference and schedule a one-on-one meeting with RESTEM’s management, please visit https://www.bio.org/events/bio-international-convention ...
Business Insider

RESTEM Announces First-Patient-Dosed in the Phase 1/2a Study of Restem-L in Facioscapulohumeral Muscular Dystrophy

− First patient with facioscapulohumeral muscular dystrophy (FSHD) dosed with Restem-L umbilical lining modified progenitor cells (UMPCs) − The Phase 1/2a study will evaluate the safety and ...
Business Insider

RESTEM to Participate in the 15th LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference in January 2026

MIAMI, Dec. 18, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today ...
Yahoo Finance

RESTEM Provides Corporate Update and Announces Strategic Priorities for 2026

MIAMI, Jan. 08, 2026 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today ...
The Manila Times

RESTEM Announces First Patient Dosed in the Phase 2/3 IIMPACT Study of Restem-L in Idiopathic Inflammatory Myopathy

Initiation of the IIMPACT study follows promising Phase 1 results where Restem-L demonstrated clinically meaningful efficacy ...